Tango Therapeutics, Inc. TNGX
Tango Therapeutics, Inc. (Nasdaq: TNGX) is an oncology drug developer. Its lead program, vopimetostat (TNG462), is in Phase 2 for MTAP-deleted cancers incl. pancreatic (PRMT5 inhibitor). Its next catalyst on record is vopimetostat: Erasca combination Phase 1/2 start (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: vopimetostat — Erasca combination Phase 1/2 start (H2 2026). 10 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| vopimetostat | MTAP-del PDAC and others | small molecule | Phase 2 |
| TNG456 | Glioblastoma | small molecule | Phase 1 |
| TNG260 | Solid tumors | small molecule | Phase 1 |
| TNG961 | Undisclosed | small molecule | Pre-clinical |
Recent results and decisions
- Oct 23, 2026positive Vopimetostat plus daraxonrasib demonstrated 82% ORR, median PFS not reached, and 88% 9-month PFS rate in 22 patients with 2L/3L MTAP-deleted PDAC.
82% objective response rate (ORR), median PFS not yet reached, and a 9-month PFS rate of 88%, in 22 patients with 2L/3L MTAP-deleted/RAS-mutant PDAC who were efficacy-evaluable.
Filing - Oct 23, 2026n/a Registrational Phase 3 study of vopimetostat plus daraxonrasib in front-line MTAP-deleted PDAC expected to initiate in first half of 2027.
Registrational Phase 3 study of vopimetostat plus daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer expected to be initiated in 1H 2027
Filing - Aug 20, 2026met Vopimetostat plus daraxonrasib achieved 82% ORR, median PFS not reached, and 88% 9-month PFS rate in 2L/3L MTAP-deleted/RAS-mutant PDAC patients (n=22).
82% objective response rate (ORR), median PFS not yet reached, and a 9-month PFS rate of 88%, in 22 patients with 2L/3L MTAP-deleted/RAS-mutant PDAC who were efficacy-evaluable.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.